{"schema_version":"secwatch.filing_event.v1","accession":"0001551986-23-000047","form_type":"8-K","ticker":null,"cik":"0001551986","company_name":"9 METERS BIOPHARMA, INC.","filed_at":"2023-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.357658+00:00","generated_at":"2026-06-14T11:39:49.807802+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"9 Meters CEO resigns; interim CEO appointed; vurolenatide Phase 2 trial planned","bullets":["CEO John Temperato resigns effective May 26, 2023; Bethany Sensenig (CFO) named interim CEO.","Separation agreement includes 12 months base salary, pro-rated 2023 bonus, and 12 months equity vesting extension.","Company revises vurolenatide plan: additional Phase 2 trial for SBS instead of Phase 3, subject to funding availability.","Company continues to assess strategic alternatives; trial timing depends on securing funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001551986-23-000047","json":"https://secwatch.observer/filing/0001551986-23-000047.json","markdown":"https://secwatch.observer/filing/0001551986-23-000047.md","text":"https://secwatch.observer/filing/0001551986-23-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551986/000155198623000047/0001551986-23-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551986/000155198623000047/nmtr-20230526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T11:39:49.807802+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d82f0730b","claim":"John Temperato resigned as Chief Executive Officer at 9 METERS BIOPHARMA, INC..","evidence_excerpt":"John Temperato, the Chief Executive Officer (the “CEO”) and a Class II director on the Board of Directors (the “Board”) of 9 Meters Biopharma, Inc. (the “Company”) resigned from his role as CEO and director of the Company, effective at the close of business on May 26, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551986/000155198623000047/0001551986-23-000047-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"fe7ce317f5","claim":"Bethany Sensenig was appointed as Interim Chief Executive Officer at 9 METERS BIOPHARMA, INC..","evidence_excerpt":"The Board appointed Bethany Sensenig, Chief Financial Officer of the Company, to serve as Interim Chief Executive Officer, and principal executive officer for SEC purposes, of the Company, in addition to her current responsibilities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551986/000155198623000047/0001551986-23-000047-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}